Cargando…

CFTR Mutations Spectrum and the Efficiency of Molecular Diagnostics in Polish Cystic Fibrosis Patients

Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane regulator gene (CFTR). In light of the strong allelic heterogeneity and regional specificity of the mutation spectrum, the strategy of molecular diagnostics and counseling in CF requires genetic tests to reflect the fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziętkiewicz, Ewa, Rutkiewicz, Ewa, Pogorzelski, Andrzej, Klimek, Barbara, Voelkel, Katarzyna, Witt, Michał
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935850/
https://www.ncbi.nlm.nih.gov/pubmed/24586523
http://dx.doi.org/10.1371/journal.pone.0089094
_version_ 1782305229867319296
author Ziętkiewicz, Ewa
Rutkiewicz, Ewa
Pogorzelski, Andrzej
Klimek, Barbara
Voelkel, Katarzyna
Witt, Michał
author_facet Ziętkiewicz, Ewa
Rutkiewicz, Ewa
Pogorzelski, Andrzej
Klimek, Barbara
Voelkel, Katarzyna
Witt, Michał
author_sort Ziętkiewicz, Ewa
collection PubMed
description Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane regulator gene (CFTR). In light of the strong allelic heterogeneity and regional specificity of the mutation spectrum, the strategy of molecular diagnostics and counseling in CF requires genetic tests to reflect the frequency profile characteristic for a given population. The goal of the study was to provide an updated comprehensive estimation of the distribution of CFTR mutations in Polish CF patients and to assess the effectiveness of INNOLiPA_CFTR tests in Polish population. The analyzed cohort consisted of 738 patients with the clinically confirmed CF diagnosis, prescreened for molecular defects using INNOLiPA_CFTR panels from Innogenetics. A combined efficiency of INNOLiPA CFTR_19 and CFTR_17_TnUpdate tests was 75.5%; both mutations were detected in 68.2%, and one mutation in 14.8% of the affected individuals. The group composed of all the patients with only one or with no mutation detected (109 and 126 individuals, respectively) was analyzed further using a mutation screening approach, i.e. SSCP/HD (single strand conformational polymorphism/heteroduplex) analysis of PCR products followed by sequencing of the coding sequence. As a result, 53 more mutations were found in 97 patients. The overall efficiency of the CF allele detection was 82.5% (7.0% increase compared to INNOLiPA tests alone). The distribution of the most frequent mutations in Poland was assessed. Most of the mutations repetitively found in Polish patients had been previously described in other European populations. The most frequent mutated allele, F508del, represented 54.5% of Polish CF chromosomes. Another eight mutations had frequencies over 1%, 24 had frequencies between 1 and 0.1%; c.2052-2053insA and c.3468+2_3468+3insT were the most frequent non-INNOLiPA mutations. Mutation distribution described herein is also relevant to the Polish diaspora. Our study also demonstrates that the reported efficiency of mutation detection strongly depends on the diagnostic experience of referring health centers.
format Online
Article
Text
id pubmed-3935850
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39358502014-03-04 CFTR Mutations Spectrum and the Efficiency of Molecular Diagnostics in Polish Cystic Fibrosis Patients Ziętkiewicz, Ewa Rutkiewicz, Ewa Pogorzelski, Andrzej Klimek, Barbara Voelkel, Katarzyna Witt, Michał PLoS One Research Article Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane regulator gene (CFTR). In light of the strong allelic heterogeneity and regional specificity of the mutation spectrum, the strategy of molecular diagnostics and counseling in CF requires genetic tests to reflect the frequency profile characteristic for a given population. The goal of the study was to provide an updated comprehensive estimation of the distribution of CFTR mutations in Polish CF patients and to assess the effectiveness of INNOLiPA_CFTR tests in Polish population. The analyzed cohort consisted of 738 patients with the clinically confirmed CF diagnosis, prescreened for molecular defects using INNOLiPA_CFTR panels from Innogenetics. A combined efficiency of INNOLiPA CFTR_19 and CFTR_17_TnUpdate tests was 75.5%; both mutations were detected in 68.2%, and one mutation in 14.8% of the affected individuals. The group composed of all the patients with only one or with no mutation detected (109 and 126 individuals, respectively) was analyzed further using a mutation screening approach, i.e. SSCP/HD (single strand conformational polymorphism/heteroduplex) analysis of PCR products followed by sequencing of the coding sequence. As a result, 53 more mutations were found in 97 patients. The overall efficiency of the CF allele detection was 82.5% (7.0% increase compared to INNOLiPA tests alone). The distribution of the most frequent mutations in Poland was assessed. Most of the mutations repetitively found in Polish patients had been previously described in other European populations. The most frequent mutated allele, F508del, represented 54.5% of Polish CF chromosomes. Another eight mutations had frequencies over 1%, 24 had frequencies between 1 and 0.1%; c.2052-2053insA and c.3468+2_3468+3insT were the most frequent non-INNOLiPA mutations. Mutation distribution described herein is also relevant to the Polish diaspora. Our study also demonstrates that the reported efficiency of mutation detection strongly depends on the diagnostic experience of referring health centers. Public Library of Science 2014-02-26 /pmc/articles/PMC3935850/ /pubmed/24586523 http://dx.doi.org/10.1371/journal.pone.0089094 Text en © 2014 Ziętkiewicz et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Ziętkiewicz, Ewa
Rutkiewicz, Ewa
Pogorzelski, Andrzej
Klimek, Barbara
Voelkel, Katarzyna
Witt, Michał
CFTR Mutations Spectrum and the Efficiency of Molecular Diagnostics in Polish Cystic Fibrosis Patients
title CFTR Mutations Spectrum and the Efficiency of Molecular Diagnostics in Polish Cystic Fibrosis Patients
title_full CFTR Mutations Spectrum and the Efficiency of Molecular Diagnostics in Polish Cystic Fibrosis Patients
title_fullStr CFTR Mutations Spectrum and the Efficiency of Molecular Diagnostics in Polish Cystic Fibrosis Patients
title_full_unstemmed CFTR Mutations Spectrum and the Efficiency of Molecular Diagnostics in Polish Cystic Fibrosis Patients
title_short CFTR Mutations Spectrum and the Efficiency of Molecular Diagnostics in Polish Cystic Fibrosis Patients
title_sort cftr mutations spectrum and the efficiency of molecular diagnostics in polish cystic fibrosis patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935850/
https://www.ncbi.nlm.nih.gov/pubmed/24586523
http://dx.doi.org/10.1371/journal.pone.0089094
work_keys_str_mv AT zietkiewiczewa cftrmutationsspectrumandtheefficiencyofmoleculardiagnosticsinpolishcysticfibrosispatients
AT rutkiewiczewa cftrmutationsspectrumandtheefficiencyofmoleculardiagnosticsinpolishcysticfibrosispatients
AT pogorzelskiandrzej cftrmutationsspectrumandtheefficiencyofmoleculardiagnosticsinpolishcysticfibrosispatients
AT klimekbarbara cftrmutationsspectrumandtheefficiencyofmoleculardiagnosticsinpolishcysticfibrosispatients
AT voelkelkatarzyna cftrmutationsspectrumandtheefficiencyofmoleculardiagnosticsinpolishcysticfibrosispatients
AT wittmichał cftrmutationsspectrumandtheefficiencyofmoleculardiagnosticsinpolishcysticfibrosispatients